Warnings on erythropoietin use in cancer patients

The MHRA and CHM have issued new prescribing recommendations for recombinant human erythropoietins (r-HuEPOs) being used to treat anaemia in cancer patients.

The new recommendations follow an analysis of available evidence that suggests patients with cancer who receive r-HuEPOs have an increased risk of tumour progression and reduced overall survival.

The decision to administer r-HuEPOs should be based on an informed risk-benefit assessment.

Blood transfusion should be the preferred option for the management of anaemia in patients with cancer, particularly in patients receiving adjuvant chemotherapy or patients being treated with curative intent.

Blood transfusion may also be preferable in patients with advanced or metastatic cancer with a good survival prognosis.

These new recommendations follow previous safety warnings from the MHRA and CHM in December 2007 given alongside recommendations for the use of r-HuEPOs for the management of anaemia in patients with chronic kidney disease.

All of these recommendations have been incorporated into the erythropoietin entries in MIMS.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases